Prosecution Insights
Last updated: April 19, 2026
Application No. 18/030,301

PROCESS FOR PREPARING BRANCHED PHENOLIC NOVOLAK

Non-Final OA §102§103
Filed
Apr 05, 2023
Examiner
FANG, SHANE
Art Unit
1766
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Advanced Polymer Coatings Inc.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
2y 6m
To Grant
95%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
1136 granted / 1491 resolved
+11.2% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
51 currently pending
Career history
1542
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
24.3%
-15.7% vs TC avg
§112
16.5%
-23.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1491 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION All the references cited in the International Search Report have been considered. The most pertinent of these references have been applied below. Election/Restrictions Applicant’s election with traverse of Group I, (claims 1-17) is acknowledged. All groups are distinct inventions and present a serious burden to the U.S. Patent and Trademark Office based on a proper lack of unity analysis. The traversal is on the ground that the restriction is only proper if the claims are independent or distinct and there would be a serious burden placed on the Examiner if restriction is not required. This is not found persuasive because the issue as to the meaning and intent regarding “independent and distinct” as used in 35 U.S.C 121 and 37 CFR 1.41, which is for national applications, but it is not used for PCT national stage (371) applications. For PCT national stage applications, restriction is based upon unity of invention; restriction of a national stage application does not take into account whether or not the inventions are independent or distinct, and does not take into account burden on the examiner. This restriction is made FINAL. The restriction and election of species as stated in the previous office action are repeated here as such. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 and 10-17 is(are) rejected under 35 U.S.C. 102(a)(1) as being anticipated by Parker et al. (US 4468507 listed on IDS and ISR). As to claims 1 and 10-17, Parker (claims, abs., examples) discloses process of producing a branched novolak comprising reacting bisphenol A with formaldehyde (HCHO: bisphenol A =4.1:1) in presence of a NaOH catalyst at 36-40 °C to form a tetramethylolated bisphenol A (EX.1, step 1, 12:5-20), followed by reacting (Ex. IC, 15:20-35) the tetramethylolated bisphenol A with o-cresol (o-cresol: tetramethyloled: bisphenol A=5:1). The branched novolak is applied as curing agent for laminates, molding, and powder coating (10:1-5,16:5-10). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 6-7 is (are) rejected under 35 U.S.C. 103(a) as being unpatentable over Parker et al. (US 4468507). Disclosure of Parker is adequately set forth in ¶1 and is incorporated herein by reference. As to claims 6-7, the polydispersity of the branched novolak resin would inherently be ≥1 (overlapping with the ranges) due to the nature of a polymer/oligomer. It has been found that where claimed ranges overlap ranges disclosed by the prior art, a prima facie case of obviousness exists - see MPEP 2144.05. Claim(s) 8-9 is (are) rejected under 35 U.S.C. 103(a) as being unpatentable over Parker et al. (US 4468507) in view of Suzuki et al. (US 20130018163). Disclosure of Parker is adequately set forth in ¶1-2 and is incorporated herein by reference. Parker teaches a generic structure of biphenol (claim 7) embracing bisphenol F and tetramethylol bisphenol F but is silent on using bisphenol F: PNG media_image1.png 200 400 media_image1.png Greyscale Z can be C1 alkylene. In the same area of endeavor of producing phenolic mold (62) comprising methylol groups (claims, abs., examples), Suzuki (62) teaches bisphenol F and bisphenol A are functionally equivalent biphenols to elevate the melting point of the resultant phenolic resin. Therefore, as to claims 8-9, it would have been obvious to one of ordinary skill in the art to have replaced bisphenol A with bisphenol F because of their equivalent functionality as primary biphenols for producing phenolic resins with elevated melting points. These conditions appear to equally apply to both productions using similar bisphenol raw materials. This adaptation would have obviously yielded instantly the tetramethylol bisphenol F of claim 9. Claim(s) 1-11 and 14-15 is (are) rejected under 35 U.S.C. 103 as being unpatentable over Maciejewski et al. (PL 177605, listed on IDS and ISR, machine translation provided) in view of Parker et al. (US 4468507) and further in view of Suzuki et al. (US 20130018163). As toc claims 1-11 and 14-15, Maciejewski (claims, abs., examples) discloses a process of producing a branched novolak having molecular weight greater than 1k for curing powder application (pg.3:3) comprising reacting phenol (188g, 2 mol) with formaldehyde (650g, 37% of formalin, 8mol) at a molar ratio of HCHO: phenol A (4:1) in presence of a NaOH catalyst to form methylolated novolak (EX.I, pg.3:4-20), followed by reacting (Ex. IC, 15:20-35) the methylolated novolak with 200g of cresol comprising o-cresol. The resultant branched novolak exhibits a Mn of 2.6k. Maciejewski is silent on the claimed biphenols. Disclosure of Parker and Suzuki is adequately set forth in ¶1-3 and is incorporated herein by reference. Therefore, as to claims 1-11 and 14-15, it would have been obvious to one of ordinary skill in the art to have modified the process disclosed by Maciejewski and replaced phenol with bisphenol F in view of Parker and Suzuki, because the resultant process would yield a branched novolak having improved melting point and branching, because bisphenol F would have more methylol (tetramethylol) sites for branching compared to phenol, as obviously recognized by one of ordinary skill in the art. Particularly to claims 2-7, the resultant bisphenol F based branched novolak would be expected to yield a Mn about 2.6k or greater than 1k (overlapping with the ranges of claims 3-4). Since the polydispersity of the branched novolak resin would inherently be ≥1 (overlapping with the ranges of claims 6-7) due to the nature of a polymer/oligomer, the resultant Mw would be expected to be ≥2.6k or ≥1k, overlapping with the claimed range. It has been found that where claimed ranges overlap ranges disclosed by the prior art, a prima facie case of obviousness exists - see MPEP 2144.05. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHANE FANG whose telephone number is (571)270-7378. The examiner can normally be reached on Mon-Thurs. 8am-6pm. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Randy Gulakowski can be reached on 571.572.1302. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHANE FANG/Primary Examiner, Art Unit 1766
Read full office action

Prosecution Timeline

Apr 05, 2023
Application Filed
Feb 04, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600818
PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS
2y 5m to grant Granted Apr 14, 2026
Patent 12595395
KIT-OF-PARTS FOR CURABLE POLYASPARTIC ACID ESTER-BASED COATING COMPOSITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595338
PROCESS FOR PREPARING A HYDROXY GROUP FUNCTIONALIZED THIOETHER
2y 5m to grant Granted Apr 07, 2026
Patent 12577411
GAS-BARRIER COATING COMPOSITION AND GAS-BARRIER LAMINATE
2y 5m to grant Granted Mar 17, 2026
Patent 12581846
ELECTROLUMINESCENT POLYMER BASED ON PHENANTHROIMIDAZOLE UNITS, PREPARATION METHOD THEREFOR, AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
95%
With Interview (+19.0%)
2y 6m
Median Time to Grant
Low
PTA Risk
Based on 1491 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month